Start with an in vitro cell model for uncharacterized novel mutations rather than proceeding directly to animal model generation, unless the functional relevance and disease phenotype of the specific alteration are already definitively established.
Your strategy depends on three core variables: baseline functional characterization (verifying downstream pathway activation, target expression, or cell viability changes in vitro), mechanistic scope (determining whether cell-autonomous assays suffice or if systemic tissue microenvironments are necessary), and resource efficiency (screening out neutral or non-pathogenic variants before committing to longer in vivo developmental timelines).
Selecting a cell model first enables rapid mechanistic confirmation via molecular assays like Western blotting and qPCR, or cellular phenotyping such as proliferation and apoptosis assays. Jumping prematurely to animal models risks substantial time and budget loss on mutations that may prove biologically silent, embryonically lethal, or phenotypically uninformative in vivo.
First identify the candidate mutation’s baseline cellular readout in stable or primary cell lines to confirm functional perturbation before transitioning into in vivo disease models. Share your target mutation and study objectives to evaluate an integrated in vitro-to-in vivo validation strategy.